In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Cancer Vaccines: Is There A Future Beyond Trial And Error?

Strong foundational research in immunology and some promising early phase trial results have so far failed to expedite the validation of vaccines to treat cancer. In Vivo examines biopharma’s enduring optimism about the future of cancer vaccinology, including a closer look at one company’s platform to tackle the incurable malignancies that beset the mother of all organs: the human brain.

Innovation ImmunoOncology Research and Development Strategies

Back To The Future: Novo’s Sørensen Reflects On CEO Years And Tasks Ahead For Industry

Lars Rebien Sørensen scrutinizes the pharmaceutical industry and shares with In Vivo his vision for the future of the Novo Nordisk Foundation. With 16 years as CEO of Novo Nordisk under his belt, as well as many more years in leadership roles at the Danish company, Sørensen reflects on the past and gives his predictions for the future of the innovative drug development sector.

Leadership Strategy Financing

Regenerative Medicine Is Here: New Payment Models Key To Patient Access

Potentially curative regenerative medicine therapies are no longer theoretical, but instead have become reality. As more and more gene, cell and tissue-based therapies reach the market, the need for payment solutions is becoming more pressing. The Alliance for Regenerative Medicine has consulted with payers and other stakeholders to consider the barriers to alternative payment models and look at possible solutions.

Regenerative Medicine Personalized Medicine Market Access

The Personal Touch: Ortho Implants Challenger Corin Creates Its Own Value Pathway

Mid-size orthopedic implants group Corin is back in the public eye after its recent purchase by a Permira-funded group. Now ready to embark on the next chapter of its development globally, it has a clear growth plan and a firm strategic line on both what it will and will not do as a business.

Innovation Orthopedics Medical Device

Datamonitor Healthcare Podcasts


 
Advertisement

Recent Tweets from In Vivo


Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Record Breaking First Half For Start-Ups Raising Cash In Europe

The first half of 2018 appeared promising for the European biopharma sector, with multiple large investment funds promising cash to young, innovative companies in the region – a turnaround after years of life science firms suffering from a funding drought across Europe.

Growth Financing

Personalization And Digital Are Pushing IVDs Onto The Health Care High Ground

Investment in advanced in vitro diagnostics is increasing as the technologies themselves are becoming less esoteric and more easily "understood" by patients and providers alike. Are these technologies finally breaking through the glass ceiling to visibly assume their rightful place in health care delivery? 

EU In Vitro Diagnostics

Bayer’s US Playbook: The Smart Way To Top-Line Growth

The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

Leadership Growth

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Brits Lead Charge In Global Battle Against Antimicrobial Resistant Superbugs

During the annual BIO International conference in June, researchers from the UK – which has pushed antimicrobial resistance to front and center on the global stage – discussed ongoing efforts for incentivizing antibiotic discovery and development, and the challenges that remain when it comes to management and resolution of the world’s AMR crisis.

Innovation Research & Development

How The EHR And New Data Streams Are Influencing Clinical Practice

A plethora of clinical studies are showing that new types of data, often captured in the EHR, can help improve the correlation between treatments and outcomes and favorably affect patient care as well as enhance drug development.

Innovation Digital Health

World In Motion – The Shape Of The New Health Care Technology Ecosystem In 2022

The health products industry, methods of care delivery and even the public's expectations for improved tools to prevent, monitor and treat disease have transformed dramatically in the past five years. The changes anticipated over a similar period ahead are potentially even more marked, with business continuity impacts for medtech and pharma concerns, according to Deloitte LLP experts who were on the circuit at health care industry events in Germany and the UK this spring.

Innovation Medical Device

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Bayer’s US Playbook: The Smart Way To Top-Line Growth

The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

Leadership Growth

Execs On The Move, June 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership Appointments

The Value Of Being Decisive On Strategic Needs – Through One Pharma CEO's Lens

After a promising research program failed to deliver, London-listed Circassia changed from being an R&D-based allergy company to one focused on commercial respiratory therapies. Rapid decision-making averted a crisis and earned the company a US deal and equity partnership with AstraZeneca. As an exercise in Plan B readiness, it's surely up there with the best.

Leadership Business Strategies

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Paying For Gene Therapy: Will Pharma Be First In Line?

With 15 new gene and cell-based therapies in late-stage testing, the time is now to consider a critical strategic question: is there a pricing model for these budget-busting treatments that works in both safeguarding returns to innovators and providing access to patients at a price society is willing to pay? An analysis by ZS Associates looks at the options for biopharma going forward.

Regenerative Medicine Market Access

Business As Usual Is Not A Vision For The Future – The Value-Based Shift Is Underway

Value is a concept that is increasingly embraced by providers and payers, as well as medtech manufacturers. Leading providers are organizing around value, changing their models and thereby inviting medtech manufacturers to adapt to the post fee-for-service era. Some, like Medtronic, are at the head of the game.

Healthcare Systems Reimbursement

Winners Are Beginning To Emerge In Digital Health – But Without Planning Medtechs Risk Missing The Boat

The leading medtechs are starting to develop models for providers that show how to implement successful digital strategies, a trend that is serving to put pressure on companies that are yet to make a commitment, says ZS Associates' Pete Masloski.

 

Market Access Digital Health

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Where Does The Field Of Regenerative Medicine Stand?

As of mid-year 2018, there were more than 950 regenerative medicine therapies in clinical trials, of which more than 90 are in Phase III. 

Regenerative Medicine Market Intelligence

Breakdown: Novo Holdings And Its Investments

Established in 1999, Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. 

Financing Market Intelligence

Deals In Depth: May 2018

In a $969 million deal, Genentech is investing in Lodo Therapeutics’ soil microbiome research to discover natural products. After several offers, Shire agreed a $79 billion takeover by Takeda, which moves into the top 10 pharma companies. Biopharma financing was slightly down while device financing increased, with a large proportion coming from FOPOs.
BioPharmaceutical Medical Device
UsernamePublicRestriction

Register

Advertisement